Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced ...
कुछ परिणाम छुपे हुए हैं क्योंकि हो सकता है वे आपके लिए पहुँच योग्य न हों.
पहुँच से बाहर के परिणामों को दिखाएँ
प्रतिक्रिया